New clinical trials in CUP and a novel paradigm in cancer classification

Elie Rassy, Fabrice André

    Research output: Contribution to journalComment/debate

    Abstract

    Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.

    Original languageEnglish
    JournalNature Reviews Clinical Oncology
    DOIs
    Publication statusAccepted/In press - 1 Jan 2024

    Cite this